Our systemic review and network meta-analysis demonstrates that NOAC and P2Y12 inhibitors may be a better choice than standard triple therapy or dual therapy with OAC and P2Y12 inhibitors in AF patients undergoing PCI. This evidence concerns the gene P2RY12 and atrial fibrillation.